Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06210035
Other study ID # UP-23-00373
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 29, 2024
Est. completion date December 31, 2024

Study information

Verified date February 2024
Source University of Southern California
Contact Kaoru Nashiro, PhD
Phone 213-761-5015
Email nashiro@usc.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In the current study, we will examine how two types of concentration meditation practices affect plasma biomarkers of Alzheimer's Disease (AD). We will also examine the effects of the two types of meditation practices on emotional well-being and episodic memory. Healthy adults aged 18-35 who meet all eligibility criteria will be invited to this study. Participants will be asked to engage in one week of daily meditation practice or no-intervention control task at home. They will also be asked to visit the lab twice, once before and once after the intervention, to provide blood samples to assess plasma biomarkers of AD and to complete emotion questionnaires and a memory test.


Recruitment information / eligibility

Status Recruiting
Enrollment 81
Est. completion date December 31, 2024
Est. primary completion date July 1, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 35 Years
Eligibility Inclusion Criteria: - Fluent in English - Aged between 18-35 years old - Agree to provide blood samples - Healthy adults who weigh at least 110 pounds - Agree to devote 40 minutes daily to this study for a week Exclusion Criteria: - Have a disorder that would affect heart rhythm or function (e.g., abnormal cardiac rhythm, dyspnea, heart disease including coronary artery disease, angina and arrhythmia) - Regularly practicing any relaxation, meditation or yoga that involve breathing focused practices lasting for more than an hour each week

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Belly-focus meditation
Participants will engage in concentration meditation for 40 minutes every day for a week. They will focus on the sensations around the belly.
Belly-focus meditation with slow breathing
Participants will engage in concentration meditation and slow breathing for 40 minutes every day for a week. They will focus on the sensations around the belly while breathing slowly.

Locations

Country Name City State
United States University of Southern California Los Angeles California

Sponsors (2)

Lead Sponsor Collaborator
University of Southern California University of California, Irvine

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Episodic memory The investigators will conduct a one-way ANOVA to assess group differences in episodic memory. Measured after a one-week intervention
Primary Change in plasma amyloid beta levels The investigators will compute an aggregate score based on both plasma Ab40 and Ab42 levels. The investigators will conduct a time (pre, post) X condition ANOVA to test for a time X condition interaction in plasma Ab levels (to assess group differences in change). Measured from blood draws before and after a one-week intervention
Primary Change in plasma Ab42/40 ratio The investigators will conduct a time X condition ANOVA to test for a time X condition interaction with plasma Ab42/40 ratio scores as the dependent variable (to assess group differences in change). Measured from blood draws before and after a one-week intervention
Secondary Change in plasma pTau-181/tau ratio The investigators will conduct a time X condition ANOVA to test for a time X condition interaction with plasma pTau-181/tau ratio as the dependent variable (to assess group differences in change). Measured from blood draws before and after a one-week intervention
Secondary Change in emotional well-being The investigators will conduct a time X condition ANOVA to test for a time X condition interaction with emotional well-being as the dependent variable (to assess group differences in change). Measured before and after a one-week intervention
See also
  Status Clinical Trial Phase
Completed NCT04079803 - PTI-125 for Mild-to-moderate Alzheimer's Disease Patients Phase 2
Completed NCT04044495 - Sleep, Rhythms and Risk of Alzheimer's Disease N/A
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT04520698 - Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease N/A
Active, not recruiting NCT04606420 - Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease N/A
Recruiting NCT05820919 - Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase N/A
Terminated NCT03672474 - REGEnLIFE RGn530 - Feasibility Pilot N/A
Completed NCT03430648 - Is Tau Protein Linked to Mobility Function?
Recruiting NCT04949750 - Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease N/A
Recruiting NCT05288842 - Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
Recruiting NCT04522739 - Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease Phase 4
Recruiting NCT05557409 - A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation Phase 3
Completed NCT06194552 - A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07 Phase 1
Completed NCT03239561 - Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants Early Phase 1
Completed NCT03184467 - Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients Phase 2
Active, not recruiting NCT03676881 - Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Terminated NCT03487380 - Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT05328115 - A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease Phase 1
Completed NCT05562583 - SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support N/A